Genworth Financial Q2 Earnings: Two Companies, One Balance Sheet

Genworth Financial reported Q2 2026 earnings on August 5 that contain two different stories in the same release. GAAP diluted EPS came in at $0.13, well below the consensus forecast of $0.28. But the adjusted operating EPS - which excludes results from the closed block of legacy long-term care policies - came to $0.29, roughly four times the adjusted estimate.

The split isn't cosmetic. It tells you exactly what Genworth's investors are buying and what they're underwriting for. The headline question is whether the open-block engine - private mortgage insurance, new LTC products through CareScout, and capital returns from Enact, the mortgage insurance provider - is strong enough to justify carrying the closed block. The factor stack suggests the answer is yes, but only if you're comfortable holding a deep-value insurance name with negative ROIC and interim management.

Valuation - A-grade discount, but the discount has a reason

Genworth trades at 0.38 times book value. That's the first number that makes investors lean forward, because no peer comes close. Aflac trades at 2.13x book, MetLife at 2.23x, Prudential at 1.21x. The gap is not a rounding error - it's a statement about what the market thinks Genworth's assets are actually worth.

The P/E multiple looks less dramatic at 17.2 times trailing earnings, which is broadly in line with MetLife (18.0x) and above Prudential (10.6x). But that trailing multiple is built on depressed GAAP earnings that include heavy charges from the LTC closed block. The forward P/E of 17.7x tells a similar story - analysts are not pricing in a dramatic reversion yet.

The book-value discount exists because Genworth's long-term care closed block has been bleeding value since the financial crisis. Rating agencies have downgraded it, states have imposed capital restrictions, and the block generated statutory losses in Q1 2026. That's why the stock trades at 62 cents below each dollar of book. The valuation looks cheap only if the open block can generate enough cash to fund buybacks and dividends while the closed block stabilizes. The factor stack says it can - but the margin for error is thin.

Growth - D-grade revenue, B-grade cash flow

Revenue growth of 1.0% year-over-year is barely positive. Q2 revenue of $1.90 billion was up from $1.78 billion in Q1, but that's more seasonal variance in the PMI cycle than structural acceleration. The PMI business is tied to mortgage origination volume, which itself is hostage to interest rates. With the Fed still navigating its rate path, Genworth's revenue growth is going to stay muted.

Where growth shows up is in free cash flow, which jumped 67.7% year-over-year. TTM FCF of $384 million on roughly $7.3 billion in annualized revenue gives a 5.3% FCF margin - not spectacular for a financial, but material for a company buying back its own stock. Genworth has repurchased $856 million of shares since the buyback program started, and the FCF expansion gives it room to continue. The capital returns from Enact also add fuel - $99 million flowed back to Genworth in Q1 alone.

The growth profile is asymmetric: top-line stagnation with bottom-line cash generation. That's a buyback-dependent thesis, which works as long as FCF doesn't reverse.

Profitability - C- on ROE, D on ROIC

ROE of 2.5% is below what any reasonable insurance peer delivers. More concerning is ROIC of negative 0.7%. A negative return on invested capital means the company's existing asset base is destroying value on a pre-financing basis. The closed block is the drag - it's a massive portfolio of legacy LTC policies whose claims costs have exceeded what the pricing assumed.

Profitability in the open block is better but not strong. Adjusted operating income of $109 million in Q1 2026, driven largely by Enact's $140 million adjusted operating income contribution, tells you that Genworth's own book isn't generating outsized returns yet. The private mortgage insurance business is profitable - PMI is always profitable in stable housing markets - but it's a volume-driven commodity business with limited pricing power.

The profitability story is one of managed decline in the closed block and modest growth in the open block. The net effect is low single-digit ROE.

Safety - B-grade capital, but CEO risk

The risk-based capital ratio (RBC - a regulatory measure of how much capital an insurer holds relative to its risk profile) sat at 289% as of March 31, which is comfortably above the company-action level. Total debt of $76.9 billion sounds alarming until you look at the structure: net debt is only $1.5 billion against $2.1 billion in cash, and debt-to-equity sits at 15.3%. The large gross debt number is inflated by insurance reserves and statutory accounting conventions - it's not corporate borrowing.

The real safety question isn't financial - it's managerial. CEO Tom McInerney, who has led Genworth since January 2013, went on indefinite medical leave on July 7. CFO Jerome Upton was named interim president and CEO. The board, through Chair Melina Higgins, said it expects continuity. But Genworth is at an inflection point between LTC remediation and open-block scaling. Executive stability matters when the strategy is balance-sheet arbitrage and one wrong underwriting call in PMI can rewind years of buybacks.

Momentum - C+ with support

The stock sits at $9.69, above its 50-day moving average ($9.33) and 200-day MA ($8.83), with a neutral RSI of 49. It's up 7.3% year-to-date and 15.5% on a rolling annual basis, but down 3.9% over the past five trading days. The 52-week range of $7.84 to $10.20 means the stock is trading in the upper third of its recent channel.

Momentum isn't a driver here. It's a confirmation that the deep-value trade is attracting attention without a blow-off. The RSI is flat, volume is modest, and the technical picture is range-bound with a slight upward tilt.

The comparison set says the discount is real, not a mispriced anomaly

Put Genworth next to its peer set and the picture sharpens:

• Aflac trades at 2.13x book, 13.8x earnings, with a $64 billion market cap. It's a clean Japanese supplementary insurance franchise with no closed-block drag.
• MetLife trades at 2.23x book, 18.0x earnings, $62 billion market cap. Global scale, institutional book, no LTC crisis legacy.
• Prudential trades at 1.21x book, 10.6x earnings, $42 billion market cap. The closest peer in terms of having some legacy complexity, but still triple Genworth's book multiple.

Genworth at 0.38x book isn't cheap because of a temporary mood swing. It's cheap because it's a $3.7 billion company carrying a multi-decade LTC liability problem on one side of its ledger while running a PMI franchise on the other. The market is pricing in the option that the closed block continues to deteriorate faster than buybacks can offset it.

AInvest's aggregate signal labels GNW a Buy, with a fundamental rating of 5.09 and composite score of 3.22. The fundamental score reflects the cheap book and positive cash flow; the middling composite reflects the growth and profitability headwinds. The signal is consistent with the factor stack: undervalued but unaccelerated.

Portfolio role: Deep value, income, with a patience requirement

Genworth belongs in the deep-value sleeve, not the growth or momentum sleeve. It's a dividend name with a 4.1% forward yield, a buyback machine that has retired $856 million of shares, and a book-value discount that would require either a closed-block resolution or sustained cash generation to compress.

It works in a low-to-moderate-rate environment where PMI volumes are stable and the dividend looks attractive versus Treasuries. It's a hedge against financial-sector rotation - if money flows from megabanks to smaller insurers, Genworth's low float and deep discount make it a candidate for re-rating.

What would break the thesis: a further LTC reserve strengthening that forces the dividend to cut or buybacks to pause, a PMI cycle downturn from rising delinquencies, or an interim CEO transition that disrupts the Enact capital-return pipeline.

What would accelerate it: continued FCF expansion supporting the buyback cadence, LTC rate actions that finally close the funding gap on legacy policies, or a strategic buyer seeing 0.38x book as an acquisition entry point.

The Q2 earnings confirmed the two-company structure. Adjusted EPS blew past expectations because the open block and Enact are working. GAAP EPS missed because the closed block is still a drag. The stock's job is to prove, quarter after quarter, that the open side is big enough to make the discount temporary. At 0.38x book, the math already assumes it isn't. The investor's job is to decide whether that assumption is too pessimistic - and whether a 4.1% dividend is adequate compensation for waiting to find out.